Daratumumab: Additional Phase II data

Data from 106 MM patients in the 2-part, open-label, international Phase II Sirius MMY2002 trial showed that 16 mg/kg daratumumab led to an ORR of 29.2%, including 3 stringent complete responses, 10 v...